Thank you, Chair, for that question.
Just broadly speaking, we had two concerns. One was about timeliness and one was about transparency. This question gets to the transparency of the regulation of drugs. In that particular recommendation, we said that Health Canada really hasn't dealt with the commitments it has made in the past to increase the transparency.